Mapping the disease-specific LupusQoL to the SF-6D

Quality of Life Research

Volumn 24, Issue 7, 2015, Pages 1749-1758

  Meacock, Rachel ^a   Harrison, Mark ^a,b,c   McElhone, Kathleen ^d   Abbott, Janice ^e   Haque, Sahena ^f   Bruce, Ian ^a,f   Teh, Lee Suan ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^e UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^f MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

LupusQoL; Mapping; Quality of life; SF 6D; Systemic lupus erythematosus; Utility

Indexed keywords

ADULT; ALGORITHM; FEMALE; HUMAN; MENTAL HEALTH; MIDDLE AGED; PAIN; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ALGORITHMS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENTAL HEALTH; MIDDLE AGED; PAIN; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84933277251     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-014-0892-4     Document Type: Article

References (47)

1. Guide to the methods of technology appraisal 2013 Foreword PMG9. (n.d.). Retrieved March 10, 2014, from http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9
2. Sullivan, S., Lyles, A., Luce, B., & Grigar, J. (n.d.). AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. Journal of Managed Care Pharmacy, 7(4), 272–282.
3. Canadian Agency for Drugs and Technologies in Health. (2006). Guidelines for the economic evaluation of health technologies. Canada. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf
4. Gold, M. R. (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
5. Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics,11(2), 215–225. doi:10.1007/s10198-009-0168-z.
6. Longworth, L., & Rowen, D. (2013). Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health,16(1), 202–210. doi:10.1016/j.jval.2012.10.010.
7. Gray, A. M., Rivero-Arias, O., & Clarke, P. M. (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making,26(1), 18–29. doi:10.1177/0272989X05284108.
8. McElhone, K., Abbott, J., Shelmerdine, J., Bruce, I. N., Ahmad, Y., Gordon, C., & Teh, L. S. (2007). Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis and Rheumatism,57(6), 972–979. doi:10.1002/art.22881.
9. O’Neill, S., & Cervera, R. (2010). Systemic lupus erythematosus. Best Practice and Research Clinical Rheumatology,24(6), 841–855. doi:10.1016/j.berh.2010.10.006.
10. Meacock, R., Dale, N., & Harrison, M. J. (2013). The humanistic and economic burden of systemic lupus erythematosus: A systematic review. Pharmacoeconomics,31(1), 49–61. doi:10.1007/s40273-012-0007-4.
11. Petri, M. (2002). Epidemiology of systemic lupus erythematosus. Best Practice and Research Clinical Rheumatology,16(5), 847–858.
12. McElhone, K., Abbott, J., & Teh, L. S. (2006). A review of health related quality of life in systemic lupus erythematosus. Lupus,15(10), 633–643.
13. Bruce, I. N. (2010). Re-evaluation of biologic therapies in systemic lupus erythematosus. Current Opinion in Rheumatology,22(3), 273–277. doi:10.1097/BOR.0b013e3283374e78.
14. Touma, Z., Gladman, D. D., Ibañez, D., & Urowitz, M. B. (2011). Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? The Journal of Rheumatology,38(9), 1898–1905. doi:10.3899/jrheum.110007.
15. Clinical Trials - Corporate Translations. (n.d.). Retrieved February 7, 2014, from http://www.corptransinc.com/Sites/LupusQoL/Instrument-Information/Clinical-Trials.aspx
16. Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007). Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care,23(1), 36–42. doi:10.1017/S0266462307051550.
17. Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics,21(2), 271–292.
18. Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care,42(9), 851–859.
19. Brazier, J., Usherwood, T., Harper, R., & Thomas, K. (1998). Deriving a preference-based single index from the UK SF-36 health survey. Journal of Clinical Epidemiology,51(11), 1115–1128. doi:10.1016/S0895-4356(98)00103-6.
20. Brazier, J. (1993). The SF-36 health survey questionnaire—A tool for economists. Health Economics,2(3), 213–215. doi:10.1002/hec.4730020304.
21. Ware, J. E., Snow, K. K., Kosinski, M., Gandek, B., & Institute NEMCHH. (1993). SF-36 health survey: Manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center.
22. Ware, J Jr, Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care,34(3), 220–233.
23. Sanchez, M., McGwin, G., Duran, S., Fernandez, M., Reveille, J., Vila, L., & Alarcon, G. (2009). Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): Use of the SF-6D. Clinical and Experimental Rheumatology,27, 64–71.
24. Aggarwal, R., Wilke, C. T., Pickard, A. S., Vats, V., Mikolaitis, R., Fogg, L., & Jolly, M. (2009). Psychometric properties of the EuroQol-5D and short form-6D in patients with systemic lupus erythematosus. The Journal of Rheumatology,36(6), 1209–1216. doi:10.3899/jrheum.081022.
25. Harrison, M. J., Ahmad, Y., Haque, S., Dale, N., Teh, L.-S., Snowden, N., & Bruce, I. N. (2012). Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus. The Journal of Rheumatology,39(4), 735–742. doi:10.3899/jrheum.110648.
26. Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, N. F., & Winchester, R. J. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism,25(11), 1271–1277.
27. Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism,40(9), 1725. doi:10.1002/1529-0131(199709)40:9&1725:AID-ART29&3.0.CO;2-Y.
28. Ahmad, Y., & Bruce, I. (2004). Sunclinical atherosclerosis in systemic lupus erythematosus. The Journal of Rheumatology,31, 841–843.
29. Hernández Alava, M., Wailoo, A. J., & Ara, R. (2012). Tails from the Peak District: Adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health,15(3), 550–561. doi:10.1016/j.jval.2011.12.014.
30. Pullenayegum, E. M., Tarride, J.-E., Xie, F., Goeree, R., Gerstein, H. C., & O’Reilly, D. (2010). Analysis of health utility data when some subjects attain the upper bound of 1: Are tobit and clad models appropriate? Value in Health,13(4), 487–494. doi:10.1111/j.1524-4733.2010.00695.x.
31. Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., & Busschbach, J. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research,22(7), 1717–1727. doi:10.1007/s11136-012-0322-4.
32. Brazier, J., Connell, J., Papaioannou, D., Mukuria, C., Mulhern, B., Peasgood, T., Parry, G. (2014). A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment doi:10.3310/hta18340.
33. Browne, C., Brazier, J., Carlton, J., Alavi, Y., & Jofre-Bonet, M. (2012). Estimating quality-adjusted life years from patient-reported visual functioning. Eye,26(10), 1295–1301. doi:10.1038/eye.2012.137.
34. Yang, Y., Wong, M. Y., Lam, C. L. K., & Wong, C. K. H. (2014). Improving the mapping of condition-specific health-related quality of life onto SF-6D score. Quality of Life Research,23(8), 2343–2353. doi:10.1007/s11136-014-0668-x.
35. Cohen, J. (1988). Statistical power analysis for the behavioral sciences. UK: Psychology Press.
36. Bansback, N., Marra, C., Tsuchiya, A., Anis, A., Guh, D., Hammond, T., & Brazier, J. (2007). Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Care & Research,57(6), 963–971. doi:10.1002/art.22885.
37. Harrison, M. J., Lunt, M., Verstappen, S. M., Watson, K. D., Bansback, N. J., & Symmons, D. P. (2010). Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health and Quality of Life Outcomes,8(1), 21. doi:10.1186/1477-7525-8-21.
38. Gabriel, S., Drummond, M., Maetzel, A., Boers, M., Coyle, D., Welch, V., & Tugwell, P. (2003). OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. The Journal of Rheumatology,30(4), 886–890.
39. Barton, G. R., Sach, T. H., Jenkinson, C., Avery, A. J., Doherty, M., & Muir, K. R. (2008). Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health and Quality of Life Outcomes,6(1), 51. doi:10.1186/1477-7525-6-51.
40. Feeny, D., Spritzer, K., Hays, R. D., Liu, H., Ganiats, T. G., Kaplan, R. M., & Fryback, D. G. (2012). Agreement about identifying patients who change over time: Cautionary results in cataract and heart failure patients. Medical Decision Making,32(2), 273–286. doi:10.1177/0272989X11418671.
41. Marra, C. A., Marion, S. A., Guh, D. P., Najafzadeh, M., Wolfe, F., Esdaile, J. M., & Anis, A. H. (2007). Not all quality-adjusted life years are equal. Journal of Clinical Epidemiology,60(6), 616–624. doi:10.1016/j.jclinepi.2006.09.006.
42. Kirwan, J. R., Boonen, A., Harrison, M. J., Hewlett, S. E., Wells, G. A., Singh, J. A., & Dworkin, R. H. (2011). OMERACT 10 patient perspective virtual Campus: Valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. The Journal of Rheumatology,38(8), 1728–1734. doi:10.3899/jrheum.110393.
43. Fayers, P. M., & Hays, R. D. (2014). Should linking replace regression when mapping from profile-based measures to preference-based measures? Value in Health,17(2), 261–265. doi:10.1016/j.jval.2013.12.002.
44. Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto the EQ-5D index: How reliable is the relationship? Health and Quality of Life Outcomes,7(1), 27. doi:10.1186/1477-7525-7-27.
45. Ara, R., & Brazier, J. (2008). Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value in Health,11(7), 1131–1143. doi:10.1111/j.1524-4733.2008.00352.x.
46. McELHONE, K., Castelino, M., Abbott, J., Bruce, I. N., Ahmad, Y., Shelmerdine, J., & Teh, L. S. (2010). The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. The Journal of Rheumatology,37(11), 2273–2279. doi:10.3899/jrheum.091277.
47. Fayers, P. M., & Hays, R. D. (2014). Don’t middle your MIDs: Regression to the mean shrinks estimates of minimally important differences. Quality of Life Research,23(1), 1–4. doi:10.1007/s11136-013-0443-4.